Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial - Concepedia

Concepedia

Publication | Open Access

Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial

DOI Full Paper Access

47

Citations

27

References

2022

Year

Keiko Imamura, Yuishin Izumi, Makiko Nagai, Kazutoshi Nishiyama, Yasuhiro Watanabe, Ritsuko Hanajima, Naohiro Egawa, Takashi Ayaki, Ryosuke Oki, Koji Fujita,

EClinicalMedicine

Abstract

AMED and iPS Cell Research Fund.

References

	Year	Citations

Page 1